Pre-exposure Prophylaxis (PrEP) Uptake and Adherence Intervention for Women With Trauma-related Conditions

November 9, 2026 updated by: Angela M Heads, The University of Texas Health Science Center, Houston

Development and Pilot Testing of a Mental Health Clinic-Based PrEP Uptake and Adherence Intervention for Women in Treatment for Trauma-Related Conditions

The investigators have previously developed an integrated bio-behavioral intervention to promote PrEP uptake and adherence in cisgender women who are undergoing treatment for trauma-related mental health conditions and who are at a higher risk for HIV. The intervention is delivered within the mental health treatment setting and integrates knowledge, behavioral skills, and motivation to engage in and adhere to PrEP care. The purpose of this study is to assess the preliminary efficacy, feasibility, and acceptability of this intervention. The hypothesis is that, compared to standard treatment, the intervention will be feasible, acceptable, and associated with greater PrEP uptake and adherence.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The new integrated intervention will include motivational counseling guided by the Information Motivation-Behavioral Skills Model (IMB) which seeks to influence behavior change via information sharing, increasing motivation for change, and teaching behavioral skills to increase self-efficacy. This novel intervention will be delivered remotely using the emocha Mobile Health smartphone application. We expect that, compared to standard SUD treatment only, the integrated intervention will be associated with higher rates of PrEP uptake and adherence.This study will 1) Collect information on knowledge and attitudes about PrEP use and obtain feedback about the potential design of the integrated behavioral intervention from women undergoing treatment for trauma-related conditions who are at risk for HIV and their providers; 2) Develop an integrated behavioral intervention to promote PrEP uptake and adherence in women undergoing treatment for trauma-related conditions who are at high risk for HIV, and 3) Assess feasibility, acceptability and initial efficacy of the intervention.

Study Type

Interventional

Enrollment (Actual)

52

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Texas
      • Houston, Texas, United States, 77054
        • Louis A. Faillace, MD, Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center at Houston

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Currently undergoing mental health treatment;
  • Have a history of trauma;
  • HIV negative;
  • Sexually active with an opposite sex partner within the past 6 months;
  • Not using PrEP for HIV prevention at the time of screening;
  • Eligible for PrEP based on having at least one Centers for Disease Control and Prevention (CDC)-defined criteria for PrEP;
  • Fluent in English;
  • Own or have regular access to a smart phone.

Exclusion Criteria:

  • HIV positive;
  • Concurrently participating in another HIV prevention program;
  • Have severe cognitive impairment that would interfere with their ability to consent, understand study procedures and/or effectively participate in therapy;
  • Have psychological distress that would prohibit them from participating in the study;
  • Be unable or unwilling to meet study requirements.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Integrated Intervention to Promote PrEP Uptake

Provision of PrEP information through 3 counseling sessions, prevention navigation, and nurse practitioner-prescribed PrEP in an addiction treatment setting.

Active Comparator: Standard Treatment Condition

Participants in trauma treatment will be given information and referral to a community partner who will evaluate them to determine if they could benefit from PrEP for HIV prevention

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of participants who uptake PrEP
Time Frame: 12 weeks post intervention

PrEP uptake is defined as obtaining a prescription and taking the first dose.

12 weeks post intervention

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Intervention feasibility as assessed by number of sessions attended by participants
Time Frame: 15 weeks post enrollment
15 weeks post enrollment
Number of Participants who adhere to PrEP
Time Frame: 12 weeks post PrEP initiation

PrEP adherence is lab confirmed and is defined as having adequate levels of tenofovir (TFV) (>1000ng/ml).

12 weeks post PrEP initiation
PrEP adherence as assessed by proportion of videos uploaded
Time Frame: from the time of PrEP initiation to 12 weeks post PrEP initiation

In the intervention arm, participants are asked to take a video of themselves taking PrEP. Videos are uploaded through an app, which is offered in the intervention arm only (and not the standard treatment arm). Data will be reported as the number of days a video is uploaded divided by the number of days of the intervention period.

from the time of PrEP initiation to 12 weeks post PrEP initiation
PrEP adherence as assessed by proportion of self-reported daily adherence
Time Frame: from the time of PrEP initiation to 12 weeks post PrEP initiation

In both arms, participants are sent a questionnaires weekly in which they record the number of days they took PrEP over the past seven days. Data will be reported as the number of days PrEP is taken divided by the number of days of the intervention period.

from the time of PrEP initiation to 12 weeks post PrEP initiation
Intervention feasibility as assessed by number of participants enrolled
Time Frame: at the time of enrollment

The number enrolled is the number of participants who signed the consent form.

at the time of enrollment
Intervention feasibility as assessed by study retention
Time Frame: 15 weeks post enrollment

Study retention is assessed by the the number of participants who completed the study.

15 weeks post enrollment
Intervention acceptability as assessed by score on a satisfaction questionnaire
Time Frame: 15 weeks post enrollment

This is a 15 item questionnaire and each item is scored from 1 (not at all true) to 9 (absolutely true). Total score ranges from 15 to 135, with a higher score indicating greater satisfaction.

15 weeks post enrollment
Change in PrEP Anticipated Stigma as assessed by the PrEP Anticipated Stigma Scale
Time Frame: baseline, 15 weeks post enrollment

Total score ranges from 8 to 32, with a higher score indicating greater stigma.

baseline, 15 weeks post enrollment
Change in perceived HIV risk as assessed by Perceived Risk of HIV Scale
Time Frame: baseline, 15 weeks post enrollment

Total score ranges from 10 to 40, with a higher score indicating a greater perceived HIV risk.

baseline, 15 weeks post enrollment
Change in PrEP knowledge as assessed by PrEP Knowledge Questionnaire
Time Frame: baseline, 15 weeks post enrollment

Total score ranges from 0 to 6, with a higher score indicating a greater knowledge about PrEP.

baseline, 15 weeks post enrollment
Change in PrEP attitudes as assessed by PrEP Attitudes Measure
Time Frame: baseline, 15 weeks post enrollment

Total score ranges from 5.2 to 26, with a higher score indicating a better attitude toward PrEP.

baseline, 15 weeks post enrollment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Angela Heads, PhD, The University of Texas Health Science Center, Houston

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 5, 2023

Primary Completion (Actual)

March 31, 2025

Study Completion (Actual)

June 30, 2026

Study Registration Dates

First Submitted

August 14, 2024

First Submitted That Met QC Criteria

August 14, 2024

First Posted (Actual)

August 19, 2024

Study Record Updates

Last Update Posted (Actual)

November 13, 2026

Last Update Submitted That Met QC Criteria

November 9, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • HSC-MS-21-0544
  • 1R34DA055496-01 (U.S. NIH Grant/Contract)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.